跳至主要内容
临床试验/RBR-8r9hy8f
RBR-8r9hy8f尚未招募2 期

A Phase 2 clinical trial of Inhaled Unfractionated Heparin (UFH) for the tretatment of Hospitalised Patients with COVID-19 - INHALE-HEP Inhaled Heparin

Galeno Desenvolvimento de Pesquisas Clínicas Ltda0 个研究点开始时间: 2021年1月6日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 80Y(—)

入选标准

  • Patients hospitalized with COVID-19 who do not require immediate mechanical ventilation (points 3-5 on the ordinal scale). Age from 18 to 80 years. Able to understand the nature and purpose of the study, including risks and adverse effects and with the intention of cooperating with the researcher and acting in accordance with the requirements of the entire trial, which is confirmed by signing the Term Informed Consent Form, prior to any study procedure. Women of childbearing potential should use a safe and effective method of contraception throughout the study. If the participant chooses to abstain from sex or practice any type of relationship that does not pose a risk of pregnancy, the use of contraception is not mandatory.

排除标准

  • The participant is known to be hypersensitive to the studied drug (heparin) or to chemically related compounds. History of serious adverse reactions or hypersensitivity to any drug. The participant has any condition that prevents him from participating in the study due to the investigator's judgment. A participant shows a positive result for beta-HCG test and/or urine test for pregnancy; delivery or abortion in the 12 weeks prior to the scheduled vaccine administration date. Present COPD.

研究者

发起方
Galeno Desenvolvimento de Pesquisas Clínicas Ltda

相似试验

A Phase 2 clinical trial of Inhaled Unfractionated... | 临床试验